Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casdozokitug + Atezolizumab + Bevacizumab in First-Line Advanced or Metastatic HCC
NCT05359861Phase 2Terminated
- Start
- Apr 2022
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 4
01
Overview
A Phase 2 trial of casdozokitug in hepatocellular carcinoma (HCC). Started Apr 2022; status: terminated.
02
Drugs
casdozokitug
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05359861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359861.